Log in

NASDAQ:AMTILegend Biotech Stock Price, Forecast & News

$27.00
+1.28 (+4.98 %)
(As of 07/3/2020 04:00 PM ET)
Add
Today's Range
$25.55
Now: $27.00
$27.48
50-Day Range N/A
52-Week Range
$17.05
Now: $27.00
$31.84
Volume428,900 shs
Average Volume740,691 shs
Market Capitalization$874.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Applied Molecular Transport Inc. develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc. was incorporated in 2010 and is based in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AMTI
CUSIPN/A
CIKN/A
Phone650-392-0420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees49
Market Cap$874.80 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for AMTI and its competitors with MarketBeat's FREE daily newsletter.

Legend Biotech (NASDAQ:AMTI) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Legend Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Legend Biotech.

What price target have analysts set for AMTI?

4 equities research analysts have issued 12-month price objectives for Legend Biotech's shares. Their forecasts range from $32.00 to $38.00. On average, they expect Legend Biotech's stock price to reach $34.50 in the next year. This suggests a possible upside of 27.8% from the stock's current price. View analysts' price targets for Legend Biotech.

Has Legend Biotech been receiving favorable news coverage?

Headlines about AMTI stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Legend Biotech earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the next several days. View the latest news about Legend Biotech.

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Dr. Tahir Mahmood Ph.D., Co-Founder, CEO & Director (Age 45)
  • Dr. Randall Mrsny Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 65)
  • Mr. Shawn M. Cross, Chief Financial Officer (Age 52)
  • Dr. Charles V. Olson, Sr. VP of Operations (Age 63)
  • Mr. Andy Whitney Ph.D., VP, Head of Preclinical Devel. & Translational Science (Age 59)

When did Legend Biotech IPO?

(AMTI) raised $130 million in an IPO on Friday, June 5th 2020. The company issued 10,000,000 shares at a price of $12.00-$14.00 per share. BofA Securities, Jefferies and SVB Leerink served as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "AMTI."

When does Legend Biotech's quiet period expire?

Legend Biotech's quiet period expires on Wednesday, July 15th. Legend Biotech had issued 11,000,000 shares in its IPO on June 5th. The total size of the offering was $154,000,000 based on an initial share price of $14.00. During Legend Biotech's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Legend Biotech?

Shares of AMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Legend Biotech's stock price today?

One share of AMTI stock can currently be purchased for approximately $27.00.

How big of a company is Legend Biotech?

Legend Biotech has a market capitalization of $874.80 million. Legend Biotech employs 49 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is www.appliedmt.com.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-392-0420.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.